Wednesday 28 February 2024
Salisbury Foundation Trust

FOI_6630

Internal Reference Number: FOI_6630

Date Request Received: 13/06/2022 00:00:00

Date Request Replied To: 20/06/2022 00:00:00

This response was sent via: By Email

Request Summary: Lung Cancer medication

Request Category: Companies

 
Question Number 1:
In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

• Afatinib
• Alectinib
• Amivantamab
• Atezolizumab monotherapy
• Atezolizumab with chemotherapy
• Brigatinib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Durvalumab
• Erlotinib
• Gefitinib
• Lorlatinib
• Mobocertinib
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Pembrolizumab monotherapy
• Pembrolizumab with chemotherapy
• Pemetrexed with Carboplatin/Cisplatin
• Sotorasib
• Tepotinib
• Vinorelbine with Carboplatin/Cisplatin
• Any other active systemic anti-cancer therapy (SACT)
• Palliative care only
 
Answer To Question 1:
• Afatinib - 0
• Alectinib - Less than 5
• Amivantamab - 0
• Atezolizumab monotherapy - Less than 5
• Atezolizumab with chemotherapy - Less than 5
• Brigatinib - 0
• Ceritinib - 0
• Crizotinib - 0
• Dacomitinib - 0
• Dabrafenib with Trametinib - 0
• Durvalumab - Less than 5
• Erlotinib - 0
• Gefitinib - Less than 5
• Lorlatinib - Less than 5
• Mobocertinib - 0
• Nintedanib with Docetaxel - 0
• Nivolumab - 0
• Osimertinib -1 1
• Pembrolizumab monotherapy -12
• Pembrolizumab with chemotherapy - 6
• Pemetrexed with Carboplatin/Cisplatin - 8
• Sotorasib - 0
• Tepotinib - 0
• Vinorelbine with Carboplatin/Cisplatin - Less than 5
• Any other active systemic anti-cancer therapy (SACT) - 0
• Palliative care only - unable to provide information
 
Question Number 2:
In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

• Atezolizumab monotherapy
• Atezolizumab with chemotherapy
• Durvalumab
• Nivolumab
• Osimertinib
• Pembrolizumab (Keytruda) Mono
• Pembrolizumab (Keytruda) with Chemotherapy
• Tepotinib
• Other active systemic anti-cancer therapy (SACT)
• Palliative care only
 
Answer To Question 2:
• Atezolizumab monotherapy - Less than 5
• Atezolizumab with chemotherapy - Less than 5
• Durvalumab - Less than 5
• Nivolumab - 0
• Osimertinib - 0
• Pembrolizumab (Keytruda) Mono - Less than 5
• Pembrolizumab (Keytruda) with Chemotherapy - 0
• Tepotinib - 0
• Other active systemic anti-cancer therapy (SACT) - 0
• Palliative care only - unable to provide information
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values